# Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

> **NCT03514069** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Case Comprehensive Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Glioma
- Glioblastoma

## Interventions

- **DRUG:** ruxolitinib
- **RADIATION:** radiation
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT03514069
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-05
- **Primary completion:** 2021-08-27
- **Final completion:** 2026-05-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03514069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03514069, "Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03514069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*